HOME >> BIOLOGY >> NEWS
Gene associatied with lupus identified

Researchers at the University of Minnesota have identified, for the first time, a gene variation associated with systemic lupus erythematosus (SLE), a complex, inflammatory autoimmune disease that affects multiple organs. The gene variation, known as PTPN22, is found in approximately 16 percent (or one in six) of healthy Caucasians in the United States. However, nearly one in four (or 23 percent) lupus patients carry this variant, which has also now been associated with risk for type 1 diabetes and rheumatoid arthritis. The study is published in the September edition of the American Journal of Human Genetics.

"This appears to be a very important gene for lupus," said Timothy W. Behrens, M.D., professor of medicine, Medical School, and principal investigator, "and this is the first time we have identified a variant that predisposes to many different autoimmune diseases. We hope that this discovery will lead to the identification of other genes associated with lupus and other immune disorders." Behrens believes that dozens of genes may be responsible for lupus and that discovering the combination of these genes will be important to developing better diagnosis and treatment of the disease.

In SLE, a person's immune system begins attacking its own tissues. Organs commonly targeted in SLE include the skin, kidneys, joints, lungs, and the central nervous system. The severity of disease and the response to therapy vary widely between patients, said Behrens, and this leads to significant challenges in the diagnosis and management of lupus. "If we know which genes predispose a person to lupus, we may be able to diagnose and treat the disease earlier," he said. "In addition to discovering which combination of genes lead to lupus and other immune diseases, we also hope this information will help us identify new drugs and therapies."


'"/>

Contact: Brenda Hudson
bhudson@umn.edu
612-624-5680
University of Chicago Press Journals
18-Aug-2004


Page: 1

Related biology news :

1. Lack of immune system protein prevents lupus-like condition in mice
2. Lupus Research Institute awards $3 million in novel research grants to further new science in lupus
3. High heart risk for lupus patients linked to death of cells lining blood vessels
4. Researchers determine a contributing genetic factor of photosensitivity in lupus patients
5. Researchers show autoantibodies occur before lupus in New England Journal of Medicine
6. Gene defect produces lupus-like disorder
7. Binding studies suggest drug development strategy for lupus
8. Treatment of lupus in mice may point the way to human treatment
9. Yale researchers shed light on B cells involvement in autoimmune diseases like lupus
10. FDA clears for market new diagnostic test for lupus
11. Biologists track down central cause of lupus

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gene associatied with lupus identified

(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/19/2014)... The empty capsules market is experiencing growth ... technological innovations in the empty capsules market. The ... growth of the empty capsules market. , Get ... of Report , The report will enrich both ... to gauge the pulse of the market which ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... Audacity, a leading California-based health and science ... Huntsworth Health Group, is proud to announce the addition ... role, Gonzales will serve as Senior Vice President of ... welcome a talent of Jamie’s caliber to the Audacity ... is a proven healthcare innovation leader and brand management ...
Breaking Biology Technology:Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
Cached News: